The Sidney Kimmel Comprehensive Cancer Center
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Employees
- -
- Market Cap
- -
3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome
- Conditions
- LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Diseases
- Locations
- 🇺🇸
M.D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
🇺🇸Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Irinotecan in Treating Patients With Progressive or Recurrent Malignant Glioma
- Conditions
- Brain and Central Nervous System Tumors
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
Fenretinide in Treating Patients With Recurrent Malignant Glioma
- Conditions
- Brain and Central Nervous System Tumors
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸UCSF Cancer Center and Cancer Research Institute, San Francisco, California, United States
🇺🇸Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease
- Conditions
- LymphomaGraft Versus Host Disease
- First Posted Date
- 2003-12-02
- Last Posted Date
- 2015-07-20
- Target Recruit Count
- 50
- Registration Number
- NCT00003414
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Rituximab in Treating Patients With Refractory or Relapsed Primary CNS Lymphoma
- Conditions
- Lymphoma
- Interventions
- Biological: rituximab
- First Posted Date
- 2003-11-06
- Last Posted Date
- 2013-08-28
- Target Recruit Count
- 12
- Registration Number
- NCT00072449
- Locations
- 🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- Radiation: radiation therapy
- First Posted Date
- 2003-09-11
- Last Posted Date
- 2015-03-18
- Target Recruit Count
- 35
- Registration Number
- NCT00068770
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy
- Conditions
- Brain and Central Nervous System Tumors
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸Neuro-Oncology Branch, Bethesda, Maryland, United States
O(6)-Benzylguanine in Treating Patients With Malignant Glioma
- Conditions
- Brain and Central Nervous System Tumors
- Locations
- 🇺🇸
UCSF Cancer Center and Cancer Research Institute, San Francisco, California, United States
🇺🇸University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States
Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma
- Conditions
- Intraocular MelanomaMelanoma (Skin)
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma
- First Posted Date
- 2003-04-09
- Last Posted Date
- 2018-08-21
- Target Recruit Count
- 55
- Registration Number
- NCT00058123
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
🇺🇸UCSF Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States